Overview and Scope
Urothelial carcinoma is a type of cancer that originates in the urothelial cells lining the inside of the urinary system, including the bladder, ureters (tubes connecting the kidneys to the bladder) and renal pelvis (the part of the kidney that collects urine). Urothelial carcinoma treatments, such as surgical interventions and intravenous therapies, control urothelial carcinoma disease, improve patient outcomes and enhance quality of life.
Sizing and Forecast
The urothelial carcinoma treatment market size has grown rapidly in recent years. It will grow from $2.41 billion in 2023 to $2.86 billion in 2024 at a compound annual growth rate (CAGR) of 18.8%. The growth in the historic period can be attributed to rising prevalence of urothelial carcinoma, growing awareness of urothelial carcinoma, increasing access to healthcare, rising disposable incomes.
The urothelial carcinoma treatment market size is expected to see rapid growth in the next few years. It will grow to $5.33 billion in 2028 at a compound annual growth rate (CAGR) of 16.9%. The growth in the forecast period can be attributed to aging population, demand for personalized medicine, rising government support for urothelial carcinoma research and treatment, growing investments on urothelial carcinoma treatment. Major trends in the forecast period include biomarker-driven therapies, neoadjuvant and adjuvant approaches, liquid biopsies, minimally invasive surgeries, chemotherapy development, digital health technologies.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/urothelial-carcinoma-treatment-global-market-report
Segmentation & Regional Insights
The urothelial carcinoma treatment market covered in this report is segmented –
1) By Type: Non-Invasive Urothelial Carcinoma Treatment; Invasive Urothelial Carcinoma Treatment
2) By Treatment: Immunotherapy; Radiotherapy; Chemotherapy
3) By Cancer Type: Bladder Cancer; Urethral Cancer; Ureteric And Renal Pelvic Cancer
4) By End-Users: Hospitals; Homecare; Specialty Centers; Other End-Users
North America was the largest region in the urothelial carcinoma treatment market in 2023. The regions covered in urothelial carcinoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12947&type=smp
Major Driver Impacting Market Growth
The increase in bladder cancer is expected to propel the growth of the urothelial carcinoma treatment market going forward. Bladder cancer is a prevalent type of cancer that affects the cells lining the urinary bladder and can lead to a range of treatment options being sought by patients and healthcare providers. Bladder cancer research informs targeted therapies and provides insights into urothelial carcinoma, fostering cross-disciplinary approaches for improved treatment outcomes. For instance, in January 2022, according to the report published by the American Cancer Society Inc., a US-based voluntary organization for cancer awareness, the estimated cases of urinary bladder cancer increased to 83,730 in 2021, an increase of 2.8% from 81,400 in 2020 in the United States. Therefore, the increase in bladder cancer will drive the urothelial carcinoma treatment market.
Key Industry Players
Major players in the urothelial carcinoma treatment market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories Inc., GlaxoSmithKline PLC, Astellas Pharma Inc., Agilent Technologies Inc., Eisai Co. Ltd., Incyte Corporation, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Seagen Inc., Lupin Limited, Genentech Inc., UroGen Pharma Inc., Acerta Pharma B.V., Asieris Pharmaceuticals Co. Ltd., Pacific Edge Limited, Protara Therapeutics Inc., Hamlet Pharma AB, CG Oncology Inc., AroCell AB, ImmunityBio Inc., IDL Biotech AB.
The urothelial carcinoma treatment market report table of contents includes:
1 . Executive Summary
- Urothelial Carcinoma Treatment Market Characteristics
- Urothelial Carcinoma Treatment Market Trends And Strategies
- Urothelial Carcinoma Treatment Market – Macro Economic Scenario
- Global Urothelial Carcinoma Treatment Market Size and Growth
. - Global Urothelial Carcinoma Treatment Market Competitive Benchmarking
- Global Urothelial Carcinoma Treatment Market Competitive Dashboard
- Key Mergers And Acquisitions In The Urothelial Carcinoma Treatment Market
- Urothelial Carcinoma Treatment Market Future Outlook and Potential Analysis
- Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
